EGFR and diffuse midline glioma: As far as the main object of this review is concerned, it is important to note that the 2021 classification, taking into account the observations of cIMPACT-NOW, has changed the name of the entire category of tumors: from the original name of 2016 (“diffuse midline glioma, H3K27M-mutant”), it has changed in 2021 to the more generic term “diffuse midline glioma, H3K27-altered,” in order to include the new biologic sub-variants that have been described between 2018 and 2021 (EZHIP and EGFR variants) (Figure 3) (3).